Psychedelics and Mental Health Series - 3/3 - Psychedelics in Practice: Conditions for a Credible Rollout

Psychedelics in Practice: The Conditions for a Credible Deployment

The previous two episodes established two conclusions. First, a coherent biological signature for psychedelics, which justifies their return to psychiatric research. Second, a methodological fragility regarding the measurement of their clinical efficacy, linked to the functional unblinding of trials. There remains a third, more pragmatic but crucial question: under what conditions could these treatments move out of research centers and reach patients?

The Real Cost of Assisted Therapy

Public debate often focuses on the price of the molecule. This is the wrong angle. The core cost of psychedelic therapy is not pharmaceutical; it is structural: it lies in the time required by a qualified practitioner to prepare the session, accompany it, and ensure follow-up.

Intranasal esketamine, approved in several countries for treatment-resistant depression, clearly illustrates this challenge. The molecule is administered under strict medical supervision, with two hours of monitoring per session, as part of a risk evaluation and mitigation program. When adding up the induction and maintenance over several months, the total cost far exceeds that of most conventional pharmacological treatments. And this cost is primarily human.

Health technology assessment agencies, such as the British NICE or the American ICER, do not reject these treatments for ideological reasons. They point out a low monetary value due to the organizational complexity of their deployment, and uncertainty regarding the duration of clinical benefits. It is a question of sustainability, not scientific hostility.

A Shortage That Is Not Pharmacological

The second bottleneck is rarely named: the availability of trained practitioners. Conducting a psychedelic-assisted therapy session requires specific training, combining psychotherapeutic skills, pharmacological knowledge, and the ability to manage sometimes intense altered states of consciousness. This training takes years, and the number of available practitioners is, in most countries, disproportionate to potential demand.

This shortage is not a technical detail. It conditions the very possibility of large-scale reimbursement. Approving a treatment that only a few dozen centers can dispense creates a two-tier system of medicine, which raises a difficult ethical question that cannot be avoided.

The Option of Non-hallucinogenic Psychoplastogens

It is in this context that a distinct research path is emerging, notably driven by the work of David E. Olson's team: developing molecules that induce the synaptic plasticity characteristic of psychedelics, but without producing their subjective effects.

Tabernanthalog, a synthetic derivative of ibogaine, is the most discussed example. In animal models, it does not produce the head-twitch response, a conventional marker of hallucinogenic activity, while still leading to comparable synaptic growth. The underlying logic is clear: if the therapeutic effect is driven by plasticity, and not by the subjective experience, then separating the two would pave the way for outpatient administration, without prolonged supervision, accessible to populations currently excluded from trials for psychiatric or cardiovascular safety reasons.

This hypothesis has not yet been proven in humans. On the contrary, part of the community argues that the subjective experience is an active element of the therapeutic process, irreducible to pharmacology. The debate is open, and it will probably be one of the most structural in the coming years.

Key Takeaways From This Episode

For the clinician, several points seem clear. Psychedelic medicine is progressing, but its integration into routine care will not be decided solely by efficacy trials. It will depend on three distinct factors: the robustness of clinical evidence under better-controlled blinding, the economic sustainability of protocols, and the development of molecules whose delivery does not overwhelm the healthcare system.

It is not a matter of choosing between supervised hallucinogens and silent psychoplastogens. Rather, it is about thinking of two complementary pathways: a specialized-center medicine for the most complex indications, and an outpatient pharmacology of plasticity for broader uses.

What is at stake, ultimately, is not so much the place of psychedelics in psychiatry as the field's ability to integrate this innovation without distorting it, and without making it a promise it cannot keep.